- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04506814
Endocardial Vs Epicardial Ablation for Recurrent Paroxysmal AF (REPEAL-AF)
Comparison of Repeat Endocardial PVI Vs Epicardial Posterior Wall Isolation and LAA Clip Plus PVI for Recurrent Atrial Fibrillation After Prior PVI
Study Overview
Status
Intervention / Treatment
Detailed Description
In these redo ablation patients, the ideal re-ablation strategy is unknown and many techniques have been proposed but there is no consensus nor strong clinical trial data.
This treatment gap prompted the development of a combined minimally invasive epicardial and endocardial ablation ("Convergent") procedure. During the last decade, this "hybrid" approach has garnered increasing acceptance in clinical practice, with several reports of promising antiarrhythmic outcomes in challenging disease states, as well as modifications to maximize safety and clinical outcomes. One key aspect of this approach is that it targets key drivers of AF including the PVs but also the left atrial posterior wall (LAPW), combining endocardial and epicardial energy delivery. The LAPW (or "PV myocardium") shares similar embryological origins and electrophysiological properties with the PVs, is predisposed to develop fibrosis, and thus recognized as an important source of AF. Recently, the CONVERGE randomized clinical trial demonstrated superiority of this hybrid approach compared to PVI in patients with persistent AF.
The left atrial appendage (LAA) has also been designated as a potential important trigger site of AF, and if isolated, may result in improved post-ablation AF outcomes. Although catheter-based isolation is controversial due to the potential to increase the risk of stroke, surgical exclusion of the LAA by placement of an occlusive clip has been suggested to be both antiarrhythmic and anti-thrombotic. Thus it is proposed in this trial to incorporate the LAA clip within the hybrid procedure.
Given the sheer volume of patients undergoing ablation of AF and the predictable necessity to perform repeat ablation procedures on a portion of these patients, the need for a proven redo ablation strategy is self-evident. The investigators thus propose a randomized clinical trial to determine if there is incremental efficacy by performing LAPW/LAA isolation via a hybrid approach in comparison to the conventional redo PVI alone in patients with paroxysmal AF.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New Jersey
-
Short Hills, New Jersey, United States, 07078
- University of Rochester
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Age > 18 years
- Symptomatic paroxysmal AF despite prior 1 or 2 PVI procedures within past 10 years (paroxysmal AF lasting up to 7 days before spontaneous termination)
- Eligible for referral for re-ablation based on current guidelines
- LA diameter < 6.0 cms on transthoracic echo
- Willingness to comply with post-procedural follow-up requirements and to sign informed consent
Exclusion Criteria
- Inability to undergo AF catheter ablation (e.g., presence of a left atrial thrombus, contraindication to anticoagulation)
- Prior history of open heart surgery
- Prior history of pericarditis or pericardiocentesis
- Prior history of stroke/TIA/systemic embolism
- NYHA class IV congestive heart failure or LVEF < 25%
- Persistent or longstanding persistent AF (duration > 1 year)
- Coronary revascularization or valve surgery within 3 months
- Prior valve surgery using a mechanical prosthesis
- An estimated glomerular filtration rate (eGFR) < 45mL/min/1.73m2, using the MDRD calculation
- Life expectancy <1 year for any medical condition
- AF due to reversible cause e.g. hyperthyroid state
- Women who are pregnant or plan to become pregnant during the course of the trial** Note: Women of childbearing potential must have a negative pregnancy test within 7 days prior to randomization.
- Participation in other clinical trials that will affect the objectives of this study
- History of non-compliance to medical therapy
- Inability or unwillingness to provide informed consent
- Resides at such a distance from the enrolling site so travel to follow-up visits would be unusually difficult
- Does not anticipate residing in the vicinity of the enrolling site for the duration of the trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Endocardial PVI
Endocardial complete PVI
|
Catheter based PVI
|
Experimental: Epicardial Posterior Wall Isolation + LAA Exclusion + Endocardial PVI
Minimally invasive surgical hybrid ablation using the convergent approach plus LAA exclusion using the clip
|
Minimally invasive PVI with posterior wall RF ablation + LAA clip + endocardial PVI
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Atrial fibrillation > 30 secs
Time Frame: At 1 year
|
Based on serial 7-day Holter recordings
|
At 1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UR Re-ablation Paroxysmal AF
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Paroxysmal Atrial Fibrillation Despite Prior Pulmonary Vein Isolation
-
Insel Gruppe AG, University Hospital BernMedtronicRecruitingArrhythmia Burden in Patients With Recurrent, Paroxysmal Atrial Fibrillation Despite Durable Pulmonary Vein IsolationSwitzerland
-
Montreal Heart InstituteCanadian Institutes of Health Research (CIHR); Johnson & Johnson; Abbott Medical...CompletedParoxysmal Atrial Fibrillation | Pulmonary Vein Isolation | Dormant Pulmonary Vein ConductionCanada, Belgium, Australia, Germany, Austria, France
-
University Medical Centre LjubljanaActive, not recruitingPulmonary Vein IsolationSlovenia
-
Deutsches Herzzentrum MuenchenCompletedImproving Outcome After Pulmonary Vein IsolationGermany
-
Institute for Clinical Effectiveness, JapanRecruitingPersistent Atrial Fibrillation | Catheter Ablation | Pulmonary Vein Isolation | Posterior Wall IsolationJapan
-
Queen Mary University of LondonCompletedAtrial Fibrillation | Atrial Fibrillation Ablation | Pulmonary Vein IsolationUnited Kingdom
-
University of LeicesterRecruitingPersistent Atrial Fibrillation | Pulmonary Vein Isolation | Atrial Fibrillation Mechanisms | Substrate Ablation | Non-contact MappingUnited Kingdom
-
University Medical Center GoettingenStereotaxisCompletedPulmonary Vein Isolation, Ablation Time, Procedure Time, Freedom Form Atrial FibrillationGermany
-
The First Affiliated Hospital with Nanjing Medical...CompletedAtrial Fibrillation | Pulmonary Vein Isolation
-
The Second Affiliated Hospital of Chongqing Medical...UnknownAtrial Fibrillation | Pulmonary Vein Isolation | CryoAblationChina
Clinical Trials on Endocardial PVI
-
Abbott Medical DevicesCompletedAtrial FibrillationCanada, Australia
-
AtriCure, Inc.Completed
-
University of RostockUnknownVentricular TachycardiaGermany
-
Meshalkin Research Institute of Pathology of CirculationUnknownAtrial Fibrillation | Arterial HypertensionRussian Federation, United States
-
Hospices Civils de LyonUnknownBrugada Syndrome Type 1France
-
AtriCure, Inc.Cardialysis BVActive, not recruitingAtrial Fibrillation | Persistent and Longstanding Persistent Atrial FibrillationGermany, United Kingdom, Netherlands, Czechia, Poland
-
Volta MedicalCovance; CardiaBaseCompletedAtrial FibrillationUnited States, Germany, Belgium, France, Netherlands
-
The Second Affiliated Hospital of Kunming Medical...Completed
-
Korea University Anam HospitalCompletedPersistent Atrial FibrillationKorea, Republic of
-
Catharina Ziekenhuis EindhovenWithdrawnHeart FailureNetherlands